Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence.

Autor: Bobin-Dubigeon C; Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes, France., Jaffré I, Joalland MP, Classe JM, Campone M, Hervé M, Bard JM
Jazyk: angličtina
Zdroj: Clinical biochemistry [Clin Biochem] 2012 Nov; Vol. 45 (16-17), pp. 1503-5. Date of Electronic Publication: 2012 May 29.
DOI: 10.1016/j.clinbiochem.2012.05.021
Abstrakt: Objective: To relate paraoxonase (PON1) activity to survival time and short term death in breast cancer recurrence.
Design and Methods: PON1 activity was measured by its rate of hydrolysis of two different substrates, paraoxon (PON) and phenylacetate (ARE) in 50 patients with recurrence of breast cancer. Results were compared between patients surviving more than one year after the analysis (22) and those who died within one year (28).
Results: In a logistic regression analysis, ARE was negatively associated with early death (OR=0.10 [0.02-0.58], p=0.0109). PON did not reach significance (OR=0.43 [0.17-1.11], p=0.0826). In a multiple logistic regression analysis model, ARE was independently associated with early death (OR=0.12 [0.02-0.98], p=0.0476), besides interval time between diagnosis and recurrence (OR=0.54 [0.27-1.07], p=0.0781) and undernutrition (OR=3.95 [0.81-19.19], p=0.0883).
Conclusion: Paraoxonase is a potential marker of survival in patients with breast cancer recurrence.
(Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: